{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:49:27Z","timestamp":1791143367717,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10555-009-9198-3","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T00:55:13Z","timestamp":1260838513000},"page":"305-316","source":"Crossref","is-referenced-by-count":139,"title":["Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Margaret A.","family":"Knowles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,16]]},"reference":[{"key":"9198_CR1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296, 1655\u20131657.","journal-title":"Science"},{"key":"9198_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","volume":"4","author":"J Luo","year":"2003","unstructured":"Luo, J., Manning, B. D., & Cantley, L. C. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and premise. Cancer Cell, 4, 257\u2013262.","journal-title":"Cancer Cell"},{"key":"9198_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw, R. J., & Cantley, L. C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424\u2013430.","journal-title":"Nature"},{"key":"9198_CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.10257","volume":"22","author":"C Eng","year":"2003","unstructured":"Eng, C. (2003). PTEN: one gene, many syndromes. Human Mutation, 22, 183\u2013198.","journal-title":"Human Mutation"},{"key":"9198_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/humu.20222","volume":"26","author":"V Launonen","year":"2005","unstructured":"Launonen, V. (2005). Mutations in the human LKB1\/STK11 gene. Human Mutation, 26, 291\u2013297.","journal-title":"Human Mutation"},{"key":"9198_CR6","first-page":"7426","volume":"61","author":"AJ Philp","year":"2001","unstructured":"Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., et al. (2001). The phosphatidylinositol 3\u2032-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Research, 61, 7426\u20137429.","journal-title":"Cancer Research"},{"key":"9198_CR7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/436792a","volume":"436","author":"DW Parsons","year":"2005","unstructured":"Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., et al. (2005). Colorectal cancer: mutations in a signalling pathway. Nature, 436, 792.","journal-title":"Nature"},{"key":"9198_CR8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","volume":"18","author":"Y Samuels","year":"2006","unstructured":"Samuels, Y., & Ericson, K. (2006). Oncogenic PI3K and its role in cancer. Current Opinion in Oncology, 18, 77\u201382.","journal-title":"Current Opinion in Oncology"},{"key":"9198_CR9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","volume":"448","author":"JD Carpten","year":"2007","unstructured":"Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 448, 439\u2013444.","journal-title":"Nature"},{"issue":"23","key":"9198_CR10","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4161\/cc.6.23.4996","volume":"66","author":"AR Ramjaun","year":"2007","unstructured":"Ramjaun, A. R., & Downward, J. (2007). Ras and phosphoinositide 3-Kinase: partners in development and tumorigenesis. Cell Cycle, 66(23), 2902\u20132905.","journal-title":"Cell Cycle"},{"key":"9198_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","volume":"121","author":"L Ma","year":"2005","unstructured":"Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell, 121, 179\u2013193.","journal-title":"Cell"},{"key":"9198_CR12","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan, T. L., & Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27, 5497\u20135510.","journal-title":"Oncogene"},{"key":"9198_CR13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"XR Wu","year":"2005","unstructured":"Wu, X. R. (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nature Reviews Cancer, 5, 713\u2013725.","journal-title":"Nature Reviews Cancer"},{"key":"9198_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/carcin\/bgi310","volume":"27","author":"MA Knowles","year":"2006","unstructured":"Knowles, M. A. (2006). Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, 27, 361\u2013373.","journal-title":"Carcinogenesis"},{"key":"9198_CR15","doi-asserted-by":"crossref","unstructured":"Knowles, M. A. (2008). Bladder cancer subtypes defined by genomic alterations. Scandinavian Journal of Urology and Nephrology 42(S218t) 116-130.","DOI":"10.1080\/03008880802284605"},{"key":"9198_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005). Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science, 307, 1098\u20131101.","journal-title":"Science"},{"key":"9198_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molcel.2008.02.024","volume":"30","author":"L Bozulic","year":"2008","unstructured":"Bozulic, L., Surucu, B., Hynx, D., & Hemmings, B. A. (2008). PKBalpha\/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Molecular Cell, 30, 203\u2013213.","journal-title":"Molecular Cell"},{"key":"9198_CR18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/sj.onc.1201154","volume":"14","author":"D Cappellen","year":"1997","unstructured":"Cappellen, D., Diez, G., de Medina, S., Chopin, D., Thiery, J. P., & Radvanyi, F. (1997). Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 14, 3059\u20133066.","journal-title":"Oncogene"},{"key":"9198_CR19","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/sj.onc.1201855","volume":"16","author":"P Cairns","year":"1998","unstructured":"Cairns, P., Evron, E., Okami, K., Halachmi, N., Esteller, M., Herman, J. G., et al. (1998). Point mutation and homozygous deletion of PTEN\/MMAC1 in primary bladder cancers. Oncogene, 16, 3215\u20133218.","journal-title":"Oncogene"},{"key":"9198_CR20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6690439","volume":"80","author":"JS Aveyard","year":"1999","unstructured":"Aveyard, J. S., Skilleter, A., Habuchi, T., & Knowles, M. A. (1999). Somatic mutation of PTEN in bladder carcinoma. British Journal of Cancer, 80, 904\u2013908.","journal-title":"British Journal of Cancer"},{"key":"9198_CR21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z","volume":"88","author":"DS Wang","year":"2000","unstructured":"Wang, D. S., Rieger-Christ, K., Latini, J. M., Moinzadeh, A., Stoffel, J., Pezza, J. A., et al. (2000). Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. International Journal of Cancer, 88, 620\u2013625.","journal-title":"International Journal of Cancer"},{"key":"9198_CR22","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","volume":"105","author":"L Zhao","year":"2008","unstructured":"Zhao, L., & Vogt, P. K. (2008). Helical domain and kinase domain mutations in p110(alpha) of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 105, 2652\u20132657.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9198_CR23","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","volume":"15","author":"FM Platt","year":"2009","unstructured":"Platt, F. M., Hurst, C. D., Taylor, C. F., Gregory, W. M., Harnden, P., & Knowles, M. A. (2009). Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clinical Cancer Research, 15, 6008\u20136017.","journal-title":"Clinical Cancer Research"},{"key":"9198_CR24","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","volume":"66","author":"E Lopez-Knowles","year":"2006","unstructured":"Lopez-Knowles, E., Hernandez, S., Malats, N., Kogevinas, M., Lloreta, J., Carrato, A., et al. (2006). PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Research, 66, 7401\u20137404.","journal-title":"Cancer Research"},{"key":"9198_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1756-0500-2-66","volume":"2","author":"CD Hurst","year":"2009","unstructured":"Hurst, C. D., Zuiverloon, T. C., Hafner, C., Zwarthoff, E. C., & Knowles, M. A. (2009). A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Research Notes, 2, 66.","journal-title":"BMC Research Notes"},{"key":"9198_CR26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","volume":"3","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y., & Velculescu, V. E. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 3, 1221\u20131224.","journal-title":"Cell Cycle"},{"key":"9198_CR27","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","volume":"24","author":"AH Jebar","year":"2005","unstructured":"Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005). FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24, 5218\u20135225.","journal-title":"Oncogene"},{"key":"9198_CR28","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","volume":"158","author":"C Billerey","year":"2001","unstructured":"Billerey, C., Chopin, D., Aubriot-Lorton, M. H., Ricol, D., Diez, G., de Medina, S., et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. American Journal of Pathology, 158, 1955\u20131959.","journal-title":"American Journal of Pathology"},{"key":"9198_CR29","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.0705218104","volume":"104","author":"C Hafner","year":"2007","unstructured":"Hafner, C., Lopez-Knowles, E., Luis, N. M., Toll, A., Baselga, E., Fernandez-Casado, A., et al. (2007). Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proceedings of the National Academy of Sciences of the United States of America, 104, 13450\u201313454.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9198_CR30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1083\/jcb.146.2.389","volume":"146","author":"J Gu","year":"1999","unstructured":"Gu, J., Tamura, M., Pankov, R., Danen, E. H., Takino, T., Matsumoto, K., et al. (1999). Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. Journal of Cell Biology, 146, 389\u2013403.","journal-title":"Journal of Cell Biology"},{"key":"9198_CR31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1242\/jcs.022459","volume":"121","author":"SM Planchon","year":"2008","unstructured":"Planchon, S. M., Waite, K. A., & Eng, C. (2008). The nuclear affairs of PTEN. Journal of Cell Science, 121, 249\u2013253.","journal-title":"Journal of Cell Science"},{"key":"9198_CR32","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.onc.1201606","volume":"16","author":"J Kagan","year":"1998","unstructured":"Kagan, J., Liu, J., Stein, J. D., Wagner, S. S., Babkowski, R., Grossman, B. H., et al. (1998). Cluster of allele losses within a 2.5\u00a0cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene, 16, 909\u2013913.","journal-title":"Oncogene"},{"key":"9198_CR33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A","volume":"29","author":"J Liu","year":"2000","unstructured":"Liu, J., Babaian, D. C., Liebert, M., Steck, P. A., & Kagan, J. (2000). Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Molecular Carcinogenesis, 29, 143\u2013150.","journal-title":"Molecular Carcinogenesis"},{"key":"9198_CR34","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1158\/0008-5472.CAN-05-4627","volume":"66","author":"H Tsuruta","year":"2006","unstructured":"Tsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., et al. (2006). Hyperplasia and carcinomas in pten-deficient mice and reduced PTEN Protein in human bladder cancer patients. Cancer Research, 66, 8389\u20138396.","journal-title":"Cancer Research"},{"key":"9198_CR35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","volume":"23","author":"AM Puzio-Kuter","year":"2009","unstructured":"Puzio-Kuter, A. M., Castillo-Martin, M., Kinkade, C. W., Wang, X., Shen, T. H., Matos, T., et al. (2009). Inactivation of p53 and Pten promotes invasive bladder cancer. Genes and Development, 23, 675\u2013680.","journal-title":"Genes and Development"},{"key":"9198_CR36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/1235","volume":"19","author":"A Cristofano Di","year":"1998","unstructured":"Di Cristofano, A., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nature Genetics, 19, 348\u2013355.","journal-title":"Nature Genetics"},{"key":"9198_CR37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1464-410X.2004.04574.x","volume":"93","author":"X Wu","year":"2004","unstructured":"Wu, X., Obata, T., Khan, Q., Highshaw, R. A., De Vere White, R., & Sweeney, C. (2004). The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU International, 93, 143\u2013150.","journal-title":"BJU International"},{"key":"9198_CR38","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/0008-5472.CAN-07-1182","volume":"68","author":"N Dey","year":"2008","unstructured":"Dey, N., Crosswell, H. E., De, P., Parsons, R., Peng, Q., Su, J. D., et al. (2008). The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Research, 68, 1862\u20131871.","journal-title":"Cancer Research"},{"key":"9198_CR39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1464-410X.2005.05642.x","volume":"96","author":"GJ Chiang","year":"2005","unstructured":"Chiang, G. J., Billmeyer, B. R., Canes, D., Stoffel, J., Moinzadeh, A., Austin, C. A., et al. (2005). The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU International, 96, 416\u2013422.","journal-title":"BJU International"},{"key":"9198_CR40","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.1038\/sj.onc.1207599","volume":"23","author":"JJ Gildea","year":"2004","unstructured":"Gildea, J. J., Herlevsen, M., Harding, M. A., Gulding, K. M., Moskaluk, C. A., Frierson, H. F., et al. (2004). PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene, 23, 6788\u20136797.","journal-title":"Oncogene"},{"key":"9198_CR41","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-05-1986","volume":"66","author":"LI Yoo","year":"2006","unstructured":"Yoo, L. I., Liu, D. W., Le Vu, S., Bronson, R. T., Wu, H., & Yuan, J. (2006). Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Research, 66, 1929\u20131939.","journal-title":"Cancer Research"},{"key":"9198_CR42","doi-asserted-by":"crossref","unstructured":"Askham, J. M., Platt, F., Chambers, P. A., Snowden, H., Taylor, C. F., & Knowles, M. A. (2009). AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene (in press)","DOI":"10.1038\/onc.2009.315"},{"key":"9198_CR43","doi-asserted-by":"crossref","unstructured":"Gomez, M., Sampson, J., & Whittemore, V. (1999). The tuberous sclerosis complex. Oxford University Press.","DOI":"10.1093\/oso\/9780195122107.001.0001"},{"key":"9198_CR44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M Slegtenhorst van","year":"1997","unstructured":"van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., et al. (1997). Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805\u2013808.","journal-title":"Science"},{"key":"9198_CR45","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"Consortium","year":"1993","unstructured":"Consortium. (1993). Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European chromosome 16 tuberous sclerosis consortium. Cell, 75, 1305\u20131315.","journal-title":"Cell"},{"key":"9198_CR46","first-page":"4766","volume":"58","author":"TL Plank","year":"1998","unstructured":"Plank, T. L., Yeung, R. S., & Henske, E. P. (1998). Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Research, 58, 4766\u20134770.","journal-title":"Cancer Research"},{"key":"9198_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1750-3639.1999.tb00209.x","volume":"9","author":"MW Johnson","year":"1999","unstructured":"Johnson, M. W., Emelin, J. K., Park, S. H., & Vinters, H. V. (1999). Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathology, 9, 45\u201354.","journal-title":"Brain Pathology"},{"key":"9198_CR48","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/hmg\/10.25.2899","volume":"10","author":"AK Hodges","year":"2001","unstructured":"Hodges, A. K., Li, S., Maynard, J., Parry, L., Braverman, R., Cheadle, J. P., et al. (2001). Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Human Molecular Genetics, 10, 2899\u20132905.","journal-title":"Human Molecular Genetics"},{"key":"9198_CR49","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki, K., Li, Y., Xu, T., & Guan, K. L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes and Development, 17, 1829\u20131834.","journal-title":"Genes and Development"},{"key":"9198_CR50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Current Biology, 13, 1259\u20131268.","journal-title":"Current Biology"},{"key":"9198_CR51","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/sj.onc.1202854","volume":"18","author":"N Hornigold","year":"1999","unstructured":"Hornigold, N., Devlin, J., Davies, A. M., Aveyard, J. S., Habuchi, T., & Knowles, M. A. (1999). Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene, 18, 2657\u20132661.","journal-title":"Oncogene"},{"key":"9198_CR52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.ju.0000074621.74361.10","volume":"170","author":"H Adachi","year":"2003","unstructured":"Adachi, H., Igawa, M., Shiina, H., Urakami, S., Shigeno, K., & Hino, O. (2003). Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. Journal of Urology, 170, 601\u2013604.","journal-title":"Journal of Urology"},{"key":"9198_CR53","first-page":"1083","volume":"8","author":"P Cairns","year":"1993","unstructured":"Cairns, P., Shaw, M. E., & Knowles, M. A. (1993). Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene, 8, 1083\u20131085.","journal-title":"Oncogene"},{"key":"9198_CR54","first-page":"1671","volume":"11","author":"T Habuchi","year":"1995","unstructured":"Habuchi, T., Devlin, J., Elder, P. A., & Knowles, M. A. (1995). Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene, 11, 1671\u20131674.","journal-title":"Oncogene"},{"key":"9198_CR55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.onc.1202277","volume":"18","author":"M Simoneau","year":"1999","unstructured":"Simoneau, M., Aboulkassim, T. O., LaRue, H., Rousseau, F., & Fradet, Y. (1999). Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene, 18, 157\u2013163.","journal-title":"Oncogene"},{"key":"9198_CR56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bjc.6690383","volume":"80","author":"AA Tilborg van","year":"1999","unstructured":"van Tilborg, A. A., Groenfeld, L. E., van der Kwast, T. H., & Zwarthoff, E. C. (1999). Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines. British Journal of Cancer, 80, 489\u2013494.","journal-title":"British Journal of Cancer"},{"key":"9198_CR57","first-page":"7652","volume":"63","author":"MA Knowles","year":"2003","unstructured":"Knowles, M. A., Habuchi, T., Kennedy, W., & Cuthbert-Heavens, D. (2003). Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Research, 63, 7652\u20137656.","journal-title":"Cancer Research"},{"key":"9198_CR58","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/hmg\/ddn098","volume":"17","author":"LS Pymar","year":"2008","unstructured":"Pymar, L. S., Platt, F. M., Askham, J. M., Morrison, E. E., & Knowles, M. A. (2008). Bladder tumour derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Human Molecular Genetics, 17, 2006\u20132017.","journal-title":"Human Molecular Genetics"},{"key":"9198_CR59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2350-10-88","volume":"10","author":"M Mozaffari","year":"2009","unstructured":"Mozaffari, M., Hoogeveen-Westerveld, M., Kwiatkowski, D., Sampson, J., Ekong, R., Povey, S., et al. (2009). Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Medical Genetic, 10, 88.","journal-title":"BMC Medical Genetic"},{"key":"9198_CR60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ejhg.2008.170","volume":"17","author":"M Nellist","year":"2009","unstructured":"Nellist, M., van den Heuvel, D., Schluep, D., Exalto, C., Goedbloed, M., Maat-Kievit, A., et al. (2009). Missense mutations to the TSC1 gene cause tuberous sclerosis complex. European Journal of Human Genetics, 17, 319\u2013328.","journal-title":"European Journal of Human Genetics"},{"key":"9198_CR61","first-page":"400","volume":"59","author":"EP Henske","year":"1996","unstructured":"Henske, E. P., Scheithauer, B. W., Short, M. P., Wollmann, R., Nahmias, J., Hornigold, N., et al. (1996). Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. American Journal of Human Genetics, 59, 400\u2013406.","journal-title":"American Journal of Human Genetics"},{"key":"9198_CR62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004390000348","volume":"107","author":"JP Cheadle","year":"2000","unstructured":"Cheadle, J. P., Reeve, M. P., Sampson, J. R., & Kwiatkowski, D. J. (2000). Molecular genetic advances in tuberous sclerosis. Human Genetics, 107, 97\u2013114.","journal-title":"Human Genetics"},{"key":"9198_CR63","doi-asserted-by":"crossref","unstructured":"Soltoff, S. P., Carraway, K. L., 3\u00a0rd, Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994). ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Molecular and Cellular Biology, 14, 3550\u20133558.","DOI":"10.1128\/MCB.14.6.3550"},{"key":"9198_CR64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-5347(17)38356-8","volume":"145","author":"M Moriyama","year":"1991","unstructured":"Moriyama, M., Akiyama, T., Yamamoto, T., Kawamoto, T., Kato, T., Sato, K., et al. (1991). Expression of c-erbB-2 gene product in urinary bladder cancer. Journal of Urology, 145, 423\u2013427.","journal-title":"Journal of Urology"},{"key":"9198_CR65","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1097-0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K","volume":"70","author":"K Sato","year":"1992","unstructured":"Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., et al. (1992). An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70, 2493\u20132498.","journal-title":"Cancer"},{"key":"9198_CR66","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/bjc.1994.220","volume":"69","author":"P Lipponen","year":"1994","unstructured":"Lipponen, P., & Eskelinen, M. (1994). Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. British Journal of Cancer, 69, 1120\u20131125.","journal-title":"British Journal of Cancer"},{"key":"9198_CR67","first-page":"1957","volume":"7","author":"NH Chow","year":"2001","unstructured":"Chow, N. H., Chan, S. H., Tzai, T. S., Ho, C. L., & Liu, H. S. (2001). Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clinical Cancer Research, 7, 1957\u20131962.","journal-title":"Clinical Cancer Research"},{"key":"9198_CR68","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.bjc.6602251","volume":"91","author":"AA Memon","year":"2004","unstructured":"Memon, A. A., Sorensen, B. S., Melgard, P., Fokdal, L., Thykjaer, T., & Nexo, E. (2004). Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. British Journal of Cancer, 91, 2034\u20132041.","journal-title":"British Journal of Cancer"},{"key":"9198_CR69","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/sj.bjc.6603154","volume":"94","author":"AA Memon","year":"2006","unstructured":"Memon, A. A., Sorensen, B. S., Meldgaard, P., Fokdal, L., Thykjaer, T., & Nexo, E. (2006). The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. British Journal of Cancer, 94, 1703\u20131709.","journal-title":"British Journal of Cancer"},{"key":"9198_CR70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2007.08.087","volume":"179","author":"W Kassouf","year":"2008","unstructured":"Kassouf, W., Black, P. C., Tuziak, T., Bondaruk, J., Lee, S., Brown, G. A., et al. (2008). Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Journal of Urology, 179, 353\u2013358.","journal-title":"Journal of Urology"},{"key":"9198_CR71","first-page":"2440","volume":"7","author":"RE Jimenez","year":"2001","unstructured":"Jimenez, R. E., Hussain, M., Bianco, F. J., Jr., Vaishampayan, U., Tabazcka, P., Sakr, W. A., et al. (2001). Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clinical Cancer Research, 7, 2440\u20132447.","journal-title":"Clinical Cancer Research"},{"key":"9198_CR72","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.10731","volume":"102","author":"S Kruger","year":"2002","unstructured":"Kruger, S., Weitsch, G., Buttner, H., Matthiensen, A., Bohmer, T., Marquardt, T., et al. (2002). HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. International Journal of Cancer, 102, 514\u2013518.","journal-title":"International Journal of Cancer"},{"key":"9198_CR73","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2002.20.6.1544","volume":"20","author":"HL Cheng","year":"2002","unstructured":"Cheng, H. L., Trink, B., Tzai, T. S., Liu, H. S., Chan, S. H., Ho, C. L., et al. (2002). Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. Journal of Clinical Oncology, 20, 1544\u20131550.","journal-title":"Journal of Clinical Oncology"},{"key":"9198_CR74","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/sj.bjc.6602593","volume":"92","author":"HL Cheng","year":"2005","unstructured":"Cheng, H. L., Liu, H. S., Lin, Y. J., Chen, H. H., Hsu, P. Y., Chang, T. Y., et al. (2005). Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. British Journal of Cancer, 92, 1906\u20131914.","journal-title":"British Journal of Cancer"},{"key":"9198_CR75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2353\/ajpath.2006.050601","volume":"168","author":"M Sanchez-Carbayo","year":"2006","unstructured":"Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Haab, B. B., & Cordon-Cardo, C. (2006). Profiling bladder cancer using targeted antibody arrays. American Journal of Pathology, 168, 93\u2013103.","journal-title":"American Journal of Pathology"},{"key":"9198_CR76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/hupa.2001.21140","volume":"32","author":"KM Rieger-Christ","year":"2001","unstructured":"Rieger-Christ, K. M., Cain, J. W., Braasch, J. W., Dugan, J. M., Silverman, M. L., Bouyounes, B., et al. (2001). Expression of classic cadherins type I in urothelial neoplastic progression. Human Pathology, 32, 18\u201323.","journal-title":"Human Pathology"},{"key":"9198_CR77","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1038\/sj.onc.1207629","volume":"23","author":"KM Rieger-Christ","year":"2004","unstructured":"Rieger-Christ, K. M., Lee, P., Zagha, R., Kosakowski, M., Moinzadeh, A., Stoffel, J., et al. (2004). Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway. Oncogene, 23, 4745\u20134753.","journal-title":"Oncogene"},{"key":"9198_CR78","doi-asserted-by":"crossref","unstructured":"di Martino, E., L\u2019Hote, C. G., Kennedy, W., Tomlinson, D. C., & Knowles, M. A. (2009). Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene (in press).","DOI":"10.1038\/onc.2009.280"},{"key":"9198_CR79","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.cub.2003.10.031","volume":"13","author":"A Woods","year":"2003","unstructured":"Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G., Neumann, D., et al. (2003). LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology, 13, 2004\u20132008.","journal-title":"Current Biology"},{"key":"9198_CR80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","volume":"6","author":"RJ Shaw","year":"2004","unstructured":"Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., et al. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91\u201399.","journal-title":"Cancer Cell"},{"key":"9198_CR81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/jama.1970.03170010074018","volume":"211","author":"RG Sommerhaug","year":"1970","unstructured":"Sommerhaug, R. G., & Mason, T. (1970). Peutz-Jeghers syndrome and ureteral polyposis. JAMA, 211, 120\u2013122.","journal-title":"JAMA"},{"key":"9198_CR82","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/sj.onc.1210594","volume":"26","author":"M Sanchez-Cespedes","year":"2007","unstructured":"Sanchez-Cespedes, M. (2007). A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene, 26, 7825\u20137832.","journal-title":"Oncogene"},{"key":"9198_CR83","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.5858\/2006-130-1865-BSCFAG","volume":"130","author":"BP Adley","year":"2006","unstructured":"Adley, B. P., Smith, N. D., Nayar, R., & Yang, X. J. (2006). Birt-Hogg-Dube syndrome: clinicopathologic findings and genetic alterations. Archives of Pathology and Laboratory Medicine, 130, 1865\u20131870.","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"9198_CR84","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer, 9, 550\u2013562.","journal-title":"Nature Reviews Cancer"},{"key":"9198_CR85","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Review Drug Discovery, 8, 627\u2013644.","journal-title":"Nature Review Drug Discovery"},{"key":"9198_CR86","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research, 66, 1500\u20131508.","journal-title":"Cancer Research"},{"key":"9198_CR87","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","volume":"25","author":"MH Hussain","year":"2007","unstructured":"Hussain, M. H., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Jr., et al. (2007). Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. Journal of Clinical Oncology, 25, 2218\u20132224.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9198-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T06:10:29Z","timestamp":1710742229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-009-9198-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":87,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["9198"],"URL":"https:\/\/doi.org\/10.1007\/s10555-009-9198-3","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}